-
Mashup Score: 0Abnormal free T4 associated with lower brain perfusion in adults - 3 year(s) ago
High and low free thyroxine levels are associated with lower global brain perfusion in adults and could lead to brain diseases, such as dementia, according to a presenter. “Thyroid function has previously been associated with dementia and neurocognitive disorders,” Oscar H. Roa Dueñas, MD, a PhD candidate at Erasmus University Medical Center in The Netherlands, told Healio.
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 7Abnormal free T4 associated with lower brain perfusion in adults - 3 year(s) ago
High and low free thyroxine levels are associated with lower global brain perfusion in adults and could lead to brain diseases, such as dementia, according to a presenter. “Thyroid function has previously been associated with dementia and neurocognitive disorders,” Oscar H. Roa Dueñas, MD, a PhD candidate at Erasmus University Medical Center in The Netherlands, told Healio.
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: "Brain perfusion could be a promising mediator in the association between #thyroid function and subsequent neurocognitive diseases.” #ATA2021 @ErasmusMC @AmThyroidAssn https://t.co/inIgA5qxmh
-
-
Mashup Score: 6Abnormal free T4 associated with lower brain perfusion in adults - 3 year(s) ago
High and low free thyroxine levels are associated with lower global brain perfusion in adults and could lead to brain diseases, such as dementia, according to a presenter. “Thyroid function has previously been associated with dementia and neurocognitive disorders,” Oscar H. Roa Dueñas, MD, a PhD candidate at Erasmus University Medical Center in The Netherlands, told Healio.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Middle-aged and older adults with low or high levels of free thyroxine have lower brain perfusion and may be at greater risk for dementia and other neurocognitive disorders, according to an #ATA2021 speaker. @ErasmusMC @AmThyroidAssn https://t.co/Grhq4D3Fy7
-
Middle-aged and older adults with low or high levels of free thyroxine have lower brain perfusion and may be at greater risk for dementia and other neurocognitive disorders, according to an #ATA2021 speaker. @ErasmusMC @AmThyroidAssn https://t.co/inIgA5qxmh
-
-
Mashup Score: 0
Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker. “Responding to initial teprotumumab (Tepezza, Horizon Therapeutics) therapy may benefit during long-term follow-up,” George J. Kahaly, MD, PhD, a professor
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “At least a large fraction of responders will go on to experience a long-term continued response over the duration of the observational period.” #TED @umichmedicine @AmThyroidAssn #ATA2021 https://t.co/JVYwlF28H6
-
-
Mashup Score: 0
Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers. The ATA and European Thyroid Association (ETA) presented a brief overview of a proposed joint consensus statement on the management of thyroid eye disease. The statement, which was drafted by a task force of seven thyroidologists and two
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “We are now in a position to select and match treatments based on what dominant feature of the individual patients.” #TED @AmThyroidAssn @ETA_Thyroid #ATA2021 https://t.co/sA0UQHox6x
-
-
Mashup Score: 0
Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker. “Responding to initial teprotumumab (Tepezza, Horizon Therapeutics) therapy may benefit during long-term follow-up,” George J. Kahaly, MD, PhD, a professor
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “Responders to initial teprotumumab therapy may benefit during long-term follow-up." #TED @umichmedicine @AmThyroidAssn #ATA2021 https://t.co/JVYwlF28H6
-
-
Mashup Score: 0
Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers. The ATA and European Thyroid Association (ETA) presented a brief overview of a proposed joint consensus statement on the management of thyroid eye disease. The statement, which was drafted by a task force of seven thyroidologists and two
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “Most decisions about treatment are best made jointly between endocrinologists and ophthalmologists, using a shared decision-making framework." #TED @AmThyroidAssn @ETA_Thyroid #ATA2021 https://t.co/sA0UQHox6x
-
-
Mashup Score: 0
Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker. “Responding to initial teprotumumab (Tepezza, Horizon Therapeutics) therapy may benefit during long-term follow-up,” George J. Kahaly, MD, PhD, a professor
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Most people who have reduced proptosis following 24 weeks of teprotumumab infusions continue to respond 120 weeks after treatment, and teprotumumab is also effective in people with longer #TED duration. @umichmedicine @AmThyroidAssn #ATA2021 https://t.co/J4JYjkxfqA
-
Most people who have reduced proptosis following 24 weeks of teprotumumab infusions continue to respond 120 weeks after treatment, and teprotumumab is also effective in people with longer #TED duration. @umichmedicine @AmThyroidAssn #ATA2021 https://t.co/JVYwlF28H6
-
-
Mashup Score: 0
Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers. The ATA and European Thyroid Association (ETA) presented a brief overview of a proposed joint consensus statement on the management of thyroid eye disease. The statement, which was drafted by a task force of seven thyroidologists and two
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
The @AmThyroidAssn and @ETA_Thyroid presented key principles from a consensus statement on #TED at #ATA2021 that focuses on individualize care and joint input from endocrinologists and ophthalmologists. https://t.co/71vKjAKu2U
-
The @AmThyroidAssn and @ETA_Thyroid presented key principles from a consensus statement on #TED at #ATA2021 that focuses on individualize care and joint input from endocrinologists and ophthalmologists. https://t.co/sA0UQHox6x
-
-
Mashup Score: 0
First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker. According to findings from a joint survey conducted by the American Thyroid Association and European Thyroid Association (ETA), providers had different opinions on first-line therapy for
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “We believe our results do have implications for research and policy. Clearly, the practice demands the need to understand who will be developing severe thyroid eye disease and how can we prevent that." @doctorjuanpa #ATA2021 @AmThyroidAssn https://t.co/1xP8UxEvPI
-
Perspective: "One might hypothesize based on these results that those with underlying cerebrovascular disease, such as prior stroke or vascular dementia, may be particularly sensitive to small changes in #thyroid hormone levels."#ATA2021 @AmThyroidAssn https://t.co/inIgA5qxmh